Deep and Durable Response of Fixed-Duration Acalabrutinib in Combination with Venetoclax, +/- Obinutuzumab in Previously Untreated Adults with CLL

In this interview, Jennifer R. Brown, Dana-Farber Cancer Institute, Boston, gives her perspective on the AMPLIFY trial – the first randomized study to evaluate the efficacy and safety of fixed-duration acalabrutinib-venetoclax (±obinutuzumab). In the MEDtalk she explains the background and aim of the AMPLIFY trial and gives her opinion about the benefit of a fixed-duration treatment. Finally, Jennifer R. Brown evaluated the use of acalabrutinib in the future treatment of CLL.